Hepatic Disorders Associated with the Use of Ivermectin for SARS-CoV-2 Infection in Adults: a Pharmacovigilance Study in VigiBase

Overview

Journal Gastroenterol Hepatol Bed Bench

Specialty Gastroenterology

Date 2023 Feb 10

PMID 36762224

Authors

Teodoro J Oscanoa

Jose Amado

Roman Romero-Ortuno

Alfonso Carvajal

Affiliations

Soon will be listed here.

Abstract

Aim: The aim of the present study was to review in VigiBase the reports of serious hepatic disorders associated with the use of ivermectin for COVID-19 in adults.

Background: In the face of the global health emergency caused by SARS-CoV-2, ivermectin, among other drugs, has been repurposed in some Latin American countries to treat COVID-19. Studies are needed on the safety of ivermectin for this new indication. VigiBase is the WHO pharmacovigilance database that registers all individual case safety reports (ICSRs) from more than 130 countries.

Methods: We extracted the ICSRs of men or women aged ≥ 18 years and dated between 1 January 2020 and 7 March 2021 which included an association with the use of ivermectin.

Results: Of 1393 ICSRs associated with ivermectin, 60 (4.3%) were registered as "serious." Ivermectin had been used for COVID-19 in 25 of those cases. Among the latter, 6 experienced hepatic disorders (hepatitis, hepatocellular injury, cholestasis, increased alanine aminotransferase and/or aspartate aminotransferase levels, abnormal liver function tests).

Conclusion: The safety of the use of ivermectin should be studied more exhaustively, especially as regards the possibility of hepatic disorders developing when the drug is used for COVID-19.

Citing Articles

Serious adverse events reported with benzimidazole derivatives: A disproportionality analysis from the World Health Organization's pharmacovigilance database.

Modingam P, Faillie J, Campillo J PLoS Negl Trop Dis. 2024; 18(11):e0012634.

PMID: 39504320 PMC: 11573212. DOI: 10.1371/journal.pntd.0012634.

Crusted Scabies in a Pediatric Liver Transplant Recipient on Immunosuppression.

Goh L, Karthik S, Nor N, Loh D, Mali V Am J Case Rep. 2024; 25:e943128.

PMID: 38971966 PMC: 11322788. DOI: 10.12659/AJCR.943128.

References

Aleem A, Mahadevaiah G, Shariff N, Kothadia J . Hepatic manifestations of COVID-19 and effect of remdesivir on liver function in patients with COVID-19 illness. Proc (Bayl Univ Med Cent). 2021; 34(4):473-477. PMC: 8224190. DOI: 10.1080/08998280.2021.1885289. View

Rodriguez Mega E . Latin America's embrace of an unproven COVID treatment is hindering drug trials. Nature. 2020; 586(7830):481-482. DOI: 10.1038/d41586-020-02958-2. View

Veit O, Beck B, Steuerwald M, Hatz C . First case of ivermectin-induced severe hepatitis. Trans R Soc Trop Med Hyg. 2006; 100(8):795-7. DOI: 10.1016/j.trstmh.2006.02.003. View

Omura S . Ivermectin: 25 years and still going strong. Int J Antimicrob Agents. 2007; 31(2):91-8. DOI: 10.1016/j.ijantimicag.2007.08.023. View

Navarro M, Camprubi D, Requena-Mendez A, Buonfrate D, Giorli G, Kamgno J . Safety of high-dose ivermectin: a systematic review and meta-analysis. J Antimicrob Chemother. 2020; 75(4):827-834. DOI: 10.1093/jac/dkz524. View

Gabrielli A, Montresor A, Chitsulo L, Engels D, Savioli L . Preventive chemotherapy in human helminthiasis: theoretical and operational aspects. Trans R Soc Trop Med Hyg. 2011; 105(12):683-93. PMC: 5576527. DOI: 10.1016/j.trstmh.2011.08.013. View

Danan G, Teschke R . RUCAM in Drug and Herb Induced Liver Injury: The Update. Int J Mol Sci. 2015; 17(1). PMC: 4730261. DOI: 10.3390/ijms17010014. View

Montastruc F, Thuriot S, Durrieu G . Hepatic Disorders With the Use of Remdesivir for Coronavirus 2019. Clin Gastroenterol Hepatol. 2020; 18(12):2835-2836. PMC: 7381904. DOI: 10.1016/j.cgh.2020.07.050. View

Heimfarth L, Santos V, Araujo A, Quintans-Junior L, Martins-Filho P . Ivermectin: Panacea or true promise for COVID-19. EXCLI J. 2021; 19:1517-1519. PMC: 7855117. DOI: 10.17179/excli2020-3022. View

10.

Guzzo C, Furtek C, Porras A, Chen C, Tipping R, Clineschmidt C . Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. J Clin Pharmacol. 2002; 42(10):1122-33. DOI: 10.1177/009127002401382731. View

11.

Padhy B, Mohanty R, Das S, Meher B . Therapeutic potential of ivermectin as add on treatment in COVID 19: A systematic review and meta-analysis. J Pharm Pharm Sci. 2020; 23:462-469. DOI: 10.18433/jpps31457. View

12.

Biour M, Ben Salem C, Chazouilleres O, Grange J, Serfaty L, Poupon R . [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]. Gastroenterol Clin Biol. 2005; 28(8-9):720-59. DOI: 10.1016/s0399-8320(04)95062-2. View

13.

Cai Q, Huang D, Yu H, Zhu Z, Xia Z, Su Y . COVID-19: Abnormal liver function tests. J Hepatol. 2020; 73(3):566-574. PMC: 7194951. DOI: 10.1016/j.jhep.2020.04.006. View

14.

Caly L, Druce J, Catton M, Jans D, Wagstaff K . The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020; 178:104787. PMC: 7129059. DOI: 10.1016/j.antiviral.2020.104787. View

15.

Kow C, Merchant H, Ul Mustafa Z, Hasan S . The association between the use of ivermectin and mortality in patients with COVID-19: a meta-analysis. Pharmacol Rep. 2021; 73(5):1473-1479. PMC: 8005369. DOI: 10.1007/s43440-021-00245-z. View

16.

Hanafy A, Abd-Elsalam S . Challenges in COVID-19 drug treatment in patients with advanced liver diseases: A hepatology perspective. World J Gastroenterol. 2020; 26(46):7272-7286. PMC: 7739155. DOI: 10.3748/wjg.v26.i46.7272. View

17.

Aithal G, Watkins P, Andrade R, Larrey D, Molokhia M, Takikawa H . Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther. 2011; 89(6):806-15. DOI: 10.1038/clpt.2011.58. View